Aquestive Therapeutics reported a third-quarter net loss of $16.5 million, or $0.13 per share, on revenues of $7.6 million, down from $12.8 million in the prior-year period due to timing fluctuations in Suboxone orders. The company announced that the FDA accepted its resubmitted New Drug Application for Anaphylm, an oral rescue medication for severe allergic reactions, assigning a PDUFA goal date of March 16, 2027. Additionally, Aquestive granted exclusive U.S. commercialization rights to Libervant to Eton Pharmaceuticals in October for a $10 million upfront payment and up to $47.5 million in milestones. The biopharmaceutical company develops medicines using innovative oral film delivery technologies.
